Xaira Therapeutics company profile: valuation, funding & revenue

This Xaira Therapeutics company profile covers the company's valuation, revenue, funding rounds, investors and history. Xaira Therapeutics works in biotech, with a focus on AI drug discovery. It was founded in 2023 and is headquartered in South San Francisco, California, United States. Every figure links to a public source, and anything the company hasn't disclosed is marked as such.

Revenue

Funding history

Xaira Therapeutics timeline

Key dates from the sources on this page, oldest first. Metric snapshots are listed after the funding events.

• 2023 — Xaira Therapeutics is founded in South San Francisco by Marc Tessier-Lavigne (CEO), Hetu Kamisetty, David Baker and others; incubated by ARCH Venture Partners and Foresite Labs.
• Apr 2024 — Launch financing: More than US$1B committed. Investors: ARCH Venture Partners and Foresite Capital (leads); F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed and others.
• April 2024 — Committed capital at launch: More than US$1 billion.

Investors

Overview

Xaira Therapeutics is an AI drug discovery and development company that launched in April 2024 with more than US$1 billion in committed capital, one of the largest launches in biotech history. It combines machine learning research, large-scale laboratory data generation and drug development, aiming to design new medicines, particularly for disease targets that have been difficult to address with conventional approaches. Its scientific foundation includes protein and antibody design methods developed in the laboratory of Nobel laureate David Baker at the University of Washington, a co-founder of Xaira.

Marc Tessier-Lavigne is Xaira's founding CEO. He is a neuroscientist who was previously chief scientific officer of Genentech, president of Rockefeller University and president of Stanford University. He resigned as Stanford's president in 2023 after a review of research papers from his former laboratory found data problems, though the review did not find that he personally manipulated data. His leadership team includes co-founder Hetu Kamisetty, a protein design scientist from the Baker lab, along with experienced drug developers. The company was incubated by ARCH Venture Partners and Foresite Labs.

What it's building

• AI models for biology: models for designing proteins and antibodies, building on methods such as RFdiffusion and RFantibody.
• Data generation: laboratory platforms that produce large biological data sets, including from perturbation experiments, to train models.
• Drug programmes: internal development of drug candidates, potentially through clinical trials.
• Integrated discovery: a combined approach from target identification to molecule design and testing.

Funding

Xaira launched with more than US$1 billion in committed financing led by ARCH Venture Partners and Foresite Capital, with investors including F-Prime, NEA, Sequoia Capital, Lux Capital and Lightspeed Venture Partners. Committed capital is typically drawn down over time rather than paid all at once. The company did not disclose a valuation, so we don't include Xaira in valuation-ranked tables, and it did not identify specific therapeutic areas at launch.

Business model

Like most biotech companies, Xaira aims to create value by developing drug candidates that can be licensed to pharmaceutical companies, partnered or taken through clinical trials and commercialised. It could also form partnerships where pharmaceutical companies pay for access to its design capabilities. Drug development takes many years and carries high failure rates, so its large funding is meant to support a long runway.

Competition

Xaira competes with AI drug discovery companies such as Isomorphic Labs, Recursion, Insitro, Generate Biomedicines, Chai Discovery and EvolutionaryScale; with large pharmaceutical companies building internal AI capabilities; and with academic labs. Its advantages are scale of funding, experienced leadership and access to leading protein design methods.

Xaira at a glance

Xaira Therapeutics is a South San Francisco AI drug discovery company that launched in April 2024 with more than US$1 billion committed, led by ARCH Venture Partners and Foresite Capital. Its CEO is Marc Tessier-Lavigne, former Genentech CSO and Stanford president, and its co-founders include Nobel laureate David Baker. It has not disclosed a valuation.

Timeline

• 2023: incubated by ARCH and Foresite Labs.
• April 2024: launches publicly with more than US$1 billion committed.
• October 2024: co-founder David Baker shares the Nobel Prize in Chemistry for computational protein design.
• 2025–2026: builds data platforms and advances research programmes.

Why protein design matters

Many medicines, including antibodies, are proteins. Designing them traditionally relied on screening huge numbers of candidates or modifying known molecules. AI protein design methods can generate entirely new proteins with desired shapes and binding properties, potentially reaching targets that were considered undruggable. David Baker's lab pioneered several of these methods, recognised by the 2024 Nobel Prize. Turning designs into safe, effective drugs still requires extensive laboratory testing and clinical trials.

The AI drug discovery debate

AI drug discovery has attracted billions in investment, but few AI-designed drugs have yet completed late-stage trials, and some early companies have struggled. Supporters argue AI can speed discovery and improve success rates; sceptics note that biology is complex and clinical trials remain the main bottleneck. Xaira's large funding allows it to pursue both technology and drug development, testing whether an integrated approach produces better results.

Who works with Xaira

Xaira's potential partners include pharmaceutical and biotech companies seeking new drug candidates and design capabilities, and patients would ultimately benefit from any successful medicines.

Risks

• Scientific risk: most drug candidates fail in development.
• Long timelines: it may take many years to show clinical results.
• Leadership scrutiny: its CEO's past research controversy could affect perception.
• Competition: many well-funded companies pursue similar goals.

Questions for partners

• Which disease areas and targets are its programmes focused on?
• What laboratory validation supports its designs?
• How would partnership economics and rights work?

How AI and lab data fit together

A central idea behind Xaira is that better AI models need better data. Public biological data is limited, noisy and often collected under different conditions. Xaira invests in laboratory platforms that generate large, consistent data sets, for example measuring how cells respond when genes are switched off or how designed proteins bind to targets. These data train models that propose new molecules, which are then made and tested in the lab, producing more data. This loop resembles the approach of other well-funded AI-for-science companies and is designed to improve predictions over time. It is expensive, which is one reason Xaira raised so much capital at launch.

Valuation context

Because Xaira hasn't disclosed a valuation, we don't rank it among unicorns. Its US$1 billion in committed capital is a measure of investor commitment, not company value, and committed funds are typically released as milestones are met.

Latest developments (October 2026)

Xaira strengthened its leadership in 2026 as it moves toward the clinic. In July it hired Ian McCaffery to lead translational science and early clinical development and promoted Ci Chu to chief discovery officer and Bo Wang to chief AI scientist, according to a Business Wire release. The company, launched in 2024 with more than US$1 billion, has not disclosed clinical trials. See our AI drug discovery guide.

What to watch

Watch for disclosed programmes, partnerships, clinical candidates and any valuation disclosure. Our guide to healthcare AI startups covers related companies.

Takeaways

Patients may eventually benefit from medicines for hard-to-treat diseases. Founders can see how large funding enables integrated AI and lab work. Investors should recognise the long timelines and uncertainty of drug development.

Sources

Every figure on this page comes from the public sources below. Where sources disagreed, we used the company's own announcement or a primary news report. Private-company data changes; check the date beside each figure.

1. BioSpace (company press release)
2. GEN